QuickView: Valneva vaccine deal
An agreement has been signed granting rights to Valneva’s EB66 cell line for clinical and commercial production of the MVA component of GeoVax’s preclinical clade C HIV vaccines for the developing world. This will allow for manufacturing of the vaccine for first clinical trials by a CMO (contract manufacturing organisation). The priority remains the lead prophylactic vaccine GOVX-B11 for the developed world, where a Phase IIb trial is being planned with the HIV Vaccine Trials Network (HVTN).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.